The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac…
By D. Silverberg, D. Wexler, M. Blum, G. Keren, D. Sheps, E. Leibovitch, D. Brosh, S. Laniado, D. Schwartz, T. Yachnin and 7 more. Journal of the American College of Cardiology, 2000
772 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Hematology
View Paper: https://www.semanticscholar.org/paper/ca37f6f7973e99fdf8d772f1cea492438b971afd
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
Citations in the corpus
- The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. (2001, methodology): “In our previous study of CHF patients (5), the treatment resulted in improved cardiac function, improved NYHA functional class, increased glomerular filtration rate, a marked reduction in the need for diuretics and a 92% reduction in the hospitalization rate compared with a similar time period befor”
- Anemia Is Common in Heart Failure and Is Associated With Poor Outcomes: Insights From a Cohort of 12 065 Patients With New-Onset Heart Failure (2003, neutral): “Cerebrovascular disease 107 (5) 58 (5) 393 (4)”
- Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. (2001, background): “(8) would suggest that partial correction of anemia to a hemoglobin level of 12 g/dl is feasible and safe in patients with severe HF.”